Future oncology最新文献

{"title":"Prognostic disparities between radioactive iodine-refractory and non-refractory DTC patients: a cohort study on survival rates and independent risk factors.","authors":"Menghua Xia, Weifu Lv, Wei Zhao, Liqin Bi, Xueran Guo, Mengxia Zhang, Liangping Shi","doi":"10.1080/14796694.2026.2715231","DOIUrl":"10.1080/14796694.2026.2715231","url":null,"abstract":"<p><strong>Aims: </strong>Patients with distant metastases of differentiated thyroid cancer (DM-DTC) exhibit significant heterogeneity in clinical characteristics and prognosis. This study aimed to investigate prognostic variables affecting overall survival (OS) in radioiodine-refractory (RAIR) patients and to predict the radioiodine therapy (RAIT) response and stimulated thyroglobulin (sTg) levels in non-radioiodine-refractory (NRAIR) patients.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 146 patients of DM-DTC undergoing RAIT, categorizing them into an RAIR group (<i>n</i> = 56) and an NRAIR group (<i>n</i> = 90). Kaplan-Meier assessed survival, Cox regression identified RAIR prognostic factors, and logistic regression explored sTg-treatment response in NRAIR.</p><p><strong>Results: </strong>The median follow-up period was 71 months (IQR: 24-132 months).In RAIR, brain metastasis (HR = 5.49, 95% CI: 1.46-20.66, <i>p</i> = 0.012) and other-site metastases (HR = 4.11, 95% CI: 1.06-15.85, <i>p</i> = 0.004) were independent poor prognostic factors. In NRAIR, sTg ≤ 75 ng/mL predicted favorable response (sensitivity 84.8%, specificity 78.9%).</p><p><strong>Conclusions: </strong>RAIR status significantly impacts DM-DTC prognosis. Brain metastases or other-site metastases are independent prognostic factors in RAIR patients, highlighting the need for stratified treatment. In NRAIR patients, preliminary data suggest that sTg ≤ 75 ng/mL predicts a favorable treatment response.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2335-2346"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540171/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148700829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in <i>EGFR</i>-altered non-small-cell lung cancer.","authors":"Natasha B Leighl, Antonio Passaro, Hiroaki Akamatsu, Alexander I Spira, Danny Nguyen, Angel Qin, Julia Schuchard, Mohamed Gamil, Mahadi Baig, Mariam Alexander","doi":"10.1080/14796694.2026.2709936","DOIUrl":"10.1080/14796694.2026.2709936","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2243-2259"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plain language summary of the ZUMA-5 study of axicabtagene ciloleucel for people with relapsed or refractory slow-growing non-Hodgkin lymphoma.","authors":"Sattva S Neelapu, Olga Nikolajeva, Caron A Jacobson","doi":"10.1080/14796694.2026.2719395","DOIUrl":"10.1080/14796694.2026.2719395","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2385-2401"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience.","authors":"Riddhi A Babel, Stephen V Liu, Tao Fan, Mayur M Amonkar, Vamsidhar Velcheti","doi":"10.1080/14796694.2026.2709201","DOIUrl":"10.1080/14796694.2026.2709201","url":null,"abstract":"<p><p>Non-small cell lung cancer (NSCLC) remains a global burden, particularly due to late‑stage diagnosis. Immune checkpoint inhibitors (ICIs) for mNSCLC, including first-line (1L) pembrolizumab regimens, significantly improved survival for these patients, establishing them as the current standard of care (SoC). Since the approvals of pembrolizumab, a large volume of real-world evidence (RWE) has been published across patient populations and with long-term follow-ups. This narrative review evaluates the available RWE on PubMed and Embase, assessing real-world clinical outcomes from 2016 to 2026 against pembrolizumab (KEYNOTE) clinical trials. Across geographies and practice settings, RWE for 1L pembrolizumab in mNSCLC is supportive of KEYNOTE findings, with survival outcomes comparable to the trials. Among heterogeneous populations, older age did not alter outcomes; however, cohorts with higher performance scores expectedly experienced poorer outcomes. Global treatment patterns highlighted pembrolizumab-containing regimens as the most administered ICI, affirming its role as SoC in 1L mNSCLC treatment. The volume of RWE studies, long-term follow-up data, and consistency in results observed across regions and diverse patient populations reinforce the use of pembrolizumab regimens as 1L SoC for patients with mNSCLC. Further analysis on the impact of heterogeneous subpopulations on the efficacy of pembrolizumab would be beneficial to support evidence-based decision-making.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2347-2366"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148619338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipid biomarkers of prostate cancer: insights from triglycerides and saturated fatty acid metabolism.","authors":"Jia Wei He, Pei Zhen Li","doi":"10.1080/14796694.2026.2707002","DOIUrl":"10.1080/14796694.2026.2707002","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer poses a substantial threat to men's health. Previous studies have hinted at potential links between dietary components like lipids and saturated fatty acids (SFAs) and prostate cancer, yet the precise relationships remain elusive.</p><p><strong>Methods: </strong>A multicenter case-control study was executed. A total of 120 pathologically confirmed prostate cancer patients and 60 age- and BMI-matched healthy male controls were enrolled. High performance liquid chromatography (HPLC) was employed to quantitatively analyze the levels of saturated, monounsaturated, and polyunsaturated fats in both prostate cancer tissues and adjacent tissues. Statistical analyses were conducted using SPSS version 23.0 software.</p><p><strong>Results: </strong>Triglycerides (OR = 4.23, 95% CI: 2.15-8.32, <i>p</i> < 0.001) and saturated fatty acid/fatty acid ratio (OR = 3.89, 95% CI: 1.98-7.64, <i>p</i> < 0.001) were significantly associated with prostate cancer risk. Both indicators were positively correlated with continuous Gleason score (triglyceride: β = 0.710, OR = 2.89, 95% CI: 1.96-4.26, <i>p</i> < 0.001; saturated fatty acid/fatty acid: β = 0.645, OR = 2.57, 95% CI: 1.78-3.71, <i>p</i> < 0.001), and were significantly elevated in prostate cancer tissues compared with adjacent non-cancerous tissues.</p><p><strong>Conclusion: </strong>This study confirms the importance of triglycerides and saturated fatty acid/fatty acid ratio in prostate cancer progression, which could be used for diagnosis and prognosis. Reducing their levels may help prevent prostate cancer.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2279-2286"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148561923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Belantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma.","authors":"Marina Samuel, Marcus S Flores, Jacob A Lowy, Michael F Rogers, Zachary M Avigan, Mohammad A Rattu, Joshua Richter","doi":"10.1080/14796694.2026.2700028","DOIUrl":"10.1080/14796694.2026.2700028","url":null,"abstract":"<p><p>Belantamab mafodotin-blmf (bela-maf) is a first-in-class antibody-drug conjugate (ADC) that targets B-cell maturation antigen (BCMA) for the treatment of multiple myeloma. Its unique structure allows it to induce plasma cell apoptosis through microtubule inhibition, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). While bela-maf failed to show efficacy as monotherapy for relapsed/refractory myeloma in its initial phase 3 trial, it subsequently showed significant improvement in progression-free survival in combination with either bortezomib/dexamethasone (BVd, DREAMM-7) or pomalidomide/dexamethasone (BPd, DREAMM-8) resulting in updated regulatory approval. Bela-maf is an \"off-the-shelf\" BCMA-directed therapy with decreased risk of severe infections compared to other T cell redirection strategies, but it results in high incidence of ocular toxicity including keratopathy, blurred vision, and dry eye due to target-independent uptake of the monomethyl auristatin F (MMAF) payload in the corneal epithelium. Bela-maf-induced ocular toxicity requires close ophthalmology monitoring and may be partially mitigated by reducing the dose or frequency of bela-maf, and further data are needed to optimize dosing strategies. Herein, we review the pharmacology, clinical efficacy, and unique safety precautions related to belantamab mafodotin, as well as highlight ongoing studies of its use in earlier lines of therapy and in combination with other anti-myeloma agents.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2131-2142"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13580488/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148404410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSMA-PET/mpMRI-guided focal dose-escalated stereotactic body radiotherapy for localized prostate cancer: study protocol for a prospective, randomized controlled trial.","authors":"Wen-Sa Peng, Wei Zou, Shanwen Chen, Haowen Jiang, En-Min Wang, Zhi-Yong Qin, Hua-Guang Zhu, Xin Wang","doi":"10.1080/14796694.2026.2714703","DOIUrl":"10.1080/14796694.2026.2714703","url":null,"abstract":"<p><p>Stereotactic body radiotherapy (SBRT) is effective for localized prostate cancer, yet many recurrences originate from the intraprostatic tumor mass (ITM). Prostate-specific membrane antigen positron emission tomography (PSMA-PET) and multiparametric magnetic resonance imaging (mpMRI) enable precise ITM localization and support focal dose escalation. This trial assesses whether PSMA-PET/mpMRI-guided boosting during SBRT improves biochemical control without excess toxicity. This is a single-center, prospective, randomized (1:1), controlled, open-label clinical trial conducted at Huashan Hospital, Fudan University. A total of 128 men with newly diagnosed localized prostate adenocarcinoma will be enrolled and randomized to receive either (1) standard SBRT (39 Gy in 6 fractions) or (2) PSMA-PET/mpMRI-guided focal dose-escalated SBRT (up to 48 Gy in 6 fractions). All participants will receive androgen deprivation therapy (ADT) according to National Comprehensive Cancer Network (NCCN) risk group and clinical practice. The primary endpoint is biochemical progression-free survival (PSA-PFS), defined by the Phoenix criteria. Secondary endpoints include local progression-free survival (LPFS), distant metastasis-free survival (DMFS), overall survival (OS), prostate cancer-specific survival (PCSS), toxicity (CTCAE v5.0), and patient-reported quality of life (EPIC-26 and SF-12). Survival outcomes will be analyzed using Kaplan-Meier estimates and compared via log-rank testing.Clinical trial registration:www.chictr.org.cnidentifier ChiCTR2500114310.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2457-2465"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging the gap: clinical practice, guidelines, reimbursement and real-world challenges in breast imaging - webinar highlights.","authors":"Joana Reis, Amy K Patel, Maria Lopes, Thiemo J A van Nijnatten, Michael Lynch, Fabiënne Ter Huurne","doi":"10.1080/14796694.2026.2706340","DOIUrl":"10.1080/14796694.2026.2706340","url":null,"abstract":"<p><p>Breast cancer is a leading cause of cancer-related mortality globally. Mammographic breast density is an identified independent risk factor to develop breast cancer. Nationwide breast cancer screening programs, which typically utilize X-ray mammography, decrease breast cancer-related deaths; however, breast density limits breast cancer detection on a mammogram. Contrast-enhanced breast imaging modalities such as magnetic resonance imaging (MRI) and the newer contrast-enhanced mammography (CEM), have utility to improve early breast cancer detection. This report summarizes discussions held during the webinar, \"Bridging the Gap: Clinical Practice, Guidelines, Reimbursement and Real-World Challenges in Breast Imaging.\" Experts from the United States and Europe examined critical aspects of breast MRI and CEM, focusing on the implementation of existing guidelines, payor policies, and barriers to their adoption. The conversation highlighted how these challenges affect broader implementation, reimbursement issues, the alignment of guidelines with payors, and patient dynamics.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2041-2046"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13456494/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148548764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized whole-genome-based ctDNA dynamics during neoadjuvant therapy across breast cancer subtypes: results from MONITOR-Breast.","authors":"Julia Foldi, Gregory Hogan, Katherine Johansen Taber, Matthew LaBella, Britney Sadler, Ravi Patel, Marija Balic, Derrick Haslem, Marcela Mazo Canola, Judy Peih-Ying Tsai, Therese Cusick, Niyati Nathwani, Yoichi Naito, Chikako Funasaka, Karlton Wong, Alexander Ham, Ashley Acevedo, C J Battey, Genevieve M Gould, Dale Muzzey, Jeff Jasper","doi":"10.1080/14796694.2026.2690165","DOIUrl":"10.1080/14796694.2026.2690165","url":null,"abstract":"<p><strong>Purpose: </strong>Pathological complete response (pCR) after neoadjuvant therapy (NAT) strongly associates with reduced breast cancer relapse risk. Circulating tumor DNA (ctDNA) shows promise as a therapy-response biomarker, but prior studies had limited sampling and assay sensitivity. MONITOR-Breast characterized ctDNA dynamics across NAT at high temporal resolution using an ultrasensitive molecular residual disease (MRD) assay.</p><p><strong>Experimental design: </strong>In this prospective observational study, 154 enrolled patients with breast cancer (all subtypes, Stages I-III) were tested at baseline, throughout NAT, and post-surgery using a whole genome sequencing-based MRD assay tracking up to 1,000 variants per patient.</p><p><strong>Results: </strong>Baseline ctDNA was detected in 93% of patients, with 20% detected in the ultrasensitive range (<100 parts per million). Post-NAT ctDNA positivity strongly associated with residual disease (RD) (odds ratio (OR)>20, <i>p</i> = 1 × 10^-7) and post-operative positivity (OR =47, <i>p</i> = 1 × 10^-6). All 56 patients with pCR and an evaluable sample had undetectable post-NAT ctDNA. Frequent testing revealed distinct patterns: 78% achieved rapid and/or sustained ctDNA clearance, while 22% exhibited persistent or intermittent positivity, and had significantly higher RD (OR =52, <i>p</i> = 3 × 10^-9), and post-operative positivity (OR =25, <i>p </i>= 1 × 10^-5).</p><p><strong>Conclusions: </strong>Frequent, ultrasensitive ctDNA assessment provided comprehensive characterization of treatment response, revealing opportunities for de-escalation in early responders and escalation in those with persistent ctDNA.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1985-1996"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148294600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease.","authors":"Anwaar Saeed, Greg Yothers, Shannon L Puhalla, Alireza Tojjari, Priya Rastogi, Tanner J Freeman, Melissa Divya Mathias, Frank A Seebach, Norman Wolmark, Thomas J George","doi":"10.1080/14796694.2026.2688569","DOIUrl":"10.1080/14796694.2026.2688569","url":null,"abstract":"<p><p>Microsatellite-stable (MSS) colorectal cancer (CRC), which accounts for approximately 85% of cases annually, has demonstrated limited responsiveness to immune checkpoint blockade in the metastatic setting. Circulating tumor DNA (ctDNA) enables sensitive detection of minimal residual disease (MRD) following curative-intent therapy and identifies patients at high risk of recurrence who may benefit from additional treatment. The EMPIRE (NSABP FC-13) study is a multicenter, open-label, randomized phase II platform trial evaluating cemiplimab-based immunotherapy in patients with MSS CRC and ctDNA-defined MRD after definitive surgery and chemotherapy. Eligible patients have postoperative ctDNA positivity in the absence of radiographic recurrence and are allocated to one of three treatment arms: cemiplimab monotherapy; cemiplimab plus fianlimab (a lymphocyte activation gene-3 inhibitor); or cemiplimab plus REGN7075 (an EGFR×CD28 costimulatory bispecific antibody). The primary endpoint is ctDNA clearance at 12 weeks assessed by tumor-informed assay, with secondary endpoints including recurrence-free survival, safety and tolerability, longitudinal ctDNA kinetics, and patterns of recurrence. Arms 2 and 3 use single-stage phase II designs, whereas Arm 1 follows a Simon two-stage design with early futility stopping. The study integrates comprehensive correlative analyses to characterize mechanisms of response and resistance.Clinical trial registration: The http://www.clinicaltrials.gov identifier is NCT07058012.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1925-1933"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390512/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148316823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}